Description

Danaher Corporation: China Headwinds Persist—But Is the Core Business Strong Enough to Offset?

Danaher Corporation reported a first quarter 2026 with mixed yet generally stable financial and operational results amid a dynamic global environment. The company generated $6.0 billion in sales, reflecting a modest 0.5% year-over-year core revenue increase. This growth was tempered by a significant 2.5% headwind mainly from a lighter-than-typical respiratory season impacting Cepheid. Excluding respiratory revenue, core revenue grew approximately 3%. Geographically, while North America showed a mid-single-digit core revenue decline, Western Europe recorded a mid-single-digit increase, and high-growth markets experienced low single-digit growth, notably driven by mid-single-digit expansion in China. Segment performance was varied. The Biotechnology segment showed strength with core revenue up 7%, driven by a high-single-digit increase in bioprocessing consumables and improving equipment order growth. Discovery and Medical segments declined low single digits, largely reflecting ongoing funding constraints at academic customers. The Life Sciences segment experienced marginal 0.